BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)

Abstract

Brain-derived neurotrophic factor (BNDF) plays a role in synapse integrity. We investigated in 398 cognitively normal adults (60±8years, 41% female, MMSE=28±1) the joint association of the Val66Met polymorphism of the BDNF gene (Met+/-) and plasma BDNF levels and abnormal cerebrospinal fluid (CSF) amyloid-beta status (A+/-) with cognitive decline and dementia risk. Age-, sex- and education-adjusted linear mixed models showed that compared to Met-A-, Met+A+ showed steeper decline on tests of global cognition, memory, language, attention and executive functioning, while Met-A+ showed steeper decline on a smaller number of tests. There were no associations between Met+A- and cognitive decline. Cox models showed that compared to Met-A-, Met+A+ participants were at increased risk of dementia (HR=8.8, 95%CI: 2.8–27.9), as were Met-A+ participants (HR=6.5, 95%CI: 2.2–19.5). Lower plasma BDNF was associated with an increased risk of progression to dementia in the A+ participants. Our results imply that Met-carriage on top of amyloid-beta pathology might increase rate of cognitive decline to dementia.
Original languageEnglish
Pages (from-to)146-154
Number of pages9
JournalNeurobiology of aging
Volume108
DOIs
Publication statusPublished - 1 Dec 2021

Keywords

  • Aged
  • Aging/genetics
  • Alzheimer Disease/genetics
  • Alzheimer's disease
  • Amyloid beta-Peptides/cerebrospinal fluid
  • Amyloid-beta
  • BDNF
  • Brain-Derived Neurotrophic Factor/blood
  • Cognition
  • Cognitive Dysfunction/genetics
  • Dementia/genetics
  • Female
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Risk
  • Subjective Cognitive Decline
  • Val66Met

Cite this